Tempus AI Posts 83% Revenue Growth, Stock Drops 7% Anyway
NEW YORK, April 24 —
Tempus AI grew revenue 83% year over year, beat EPS estimates, and still lost 7% of its market value.
- Revenue hit $1.3bn TTM on 83% YoY growth, with EPS coming in above consensus
- Shares trade at a negative 571.8x forward P/E, meaning the company still isn't expected to earn real money soon
- New USC partnership covers 1.5 million annual patient visits, but no disclosed revenue terms yet
What Actually Happened
Tempus delivered the kind of quarter most companies would frame and hang on the wall. Revenue growth of 83% is legitimately fast for a company already running at $1.3bn TTM. The EPS beat, while still deeply negative, showed the loss trajectory is at least narrowing against expectations.
The USC deal is the splashier headline. The University of Southern California health system will deploy Tempus's AI-driven precision medicine tools across its network, touching 1.5 million patient visits per year. That's a real institution lending its credibility to the platform. For a company trying to prove its tech works at scale inside actual clinical workflows, this is the kind of proof point that matters.
So why did the stock drop? Because at $51.7 per share with a negative forward P/E of 571.8x, Tempus was priced for something closer to miraculous. An earnings beat and a partnership announcement are good. They just aren't good enough when the market already baked in a best-case scenario.
The Catch
The USC partnership sounds transformative, but there are no disclosed financial terms. "1.5 million patient visits" is a volume number, not a revenue number. Healthcare AI partnerships have a long history of generating impressive press releases and modest invoices. The gap between "deployed across a system" and "generating material per-patient revenue" can take years to close.
The deeper issue is profitability. At negative 571.8x forward P/E, the market is telling you this company won't produce meaningful earnings anytime soon. Revenue growth of 83% is excellent, but investors have watched enough high-growth healthcare tech stories to know that growth without a visible path to positive earnings eventually exhausts even the most patient capital. Tempus needs to show that each incremental dollar of revenue moves the margin structure, not just the top line.
Bottom Line
This is a stock where the business is executing and the valuation is punishing it for not executing fast enough. If you believe precision medicine AI is a generational shift in healthcare delivery, Tempus is building one of the stronger platforms. If you need to see earnings before you believe, there's nothing in this quarter to change your mind. The number to watch next quarter is whether revenue growth stays above 70% and whether management gives any financial sizing on the USC deal.
Tempus AI doesn't have a Basis Report yet. Generate a full TEM analysis here to dig into the financials.
Basis Report does not hold positions in securities discussed. This is not investment advice.